News

Text on blue background: "Belzutifan approved for Pheo Para"
Blog

Belzutifan Approved for Pheo Para

In a breakthrough for those with advanced pheochromocytoma and paraganglioma (Pheo/Para), the U.S. Food and Drug Administration (FDA) has approved WELIREG® (belzutifan) as a treatment

Read More »
Blog

A New Treatment Option for NET Patients

The U.S. Food and Drug Administration (FDA) has approved cabozantinib for the treatment of previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors

Read More »